Merus NV (MRUS)
44.52
-0.60
(-1.33%)
USD |
NASDAQ |
May 10, 16:00
44.50
-0.02
(-0.06%)
After-Hours: 20:00
Merus Revenue (Quarterly): 8.939M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 8.939M |
| September 30, 2023 | 11.03M |
| June 30, 2023 | 10.48M |
| March 31, 2023 | 13.50M |
| December 31, 2022 | 10.67M |
| September 30, 2022 | 6.581M |
| June 30, 2022 | 12.68M |
| March 31, 2022 | 11.66M |
| December 31, 2021 | 14.71M |
| September 30, 2021 | 13.67M |
| June 30, 2021 | 12.38M |
| March 31, 2021 | 8.35M |
| December 31, 2020 | 9.016M |
| September 30, 2020 | 8.57M |
| June 30, 2020 | 6.056M |
| March 31, 2020 | 6.301M |
| December 31, 2019 | 7.792M |
| September 30, 2019 | 8.155M |
| June 30, 2019 | 6.357M |
| Date | Value |
|---|---|
| March 31, 2019 | 8.829M |
| December 31, 2018 | 11.91M |
| September 30, 2018 | 7.553M |
| June 30, 2018 | 7.433M |
| March 31, 2018 | 12.15M |
| December 31, 2017 | 7.257M |
| September 30, 2017 | 6.694M |
| June 30, 2017 | 6.228M |
| March 31, 2017 | 4.109M |
| December 31, 2016 | -0.0979M |
| September 30, 2016 | 1.001M |
| June 30, 2016 | 0.2136M |
| March 31, 2016 | 0.0635M |
| December 31, 2015 | 0.0211M |
| September 30, 2015 | 0.1091M |
| June 30, 2015 | 1.240M |
| March 31, 2015 | 0.0606M |
| December 31, 2014 | 0.4779M |
| September 30, 2014 | 0.3974M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
6.056M
Minimum
Jun 2020
14.71M
Maximum
Dec 2021
9.836M
Average
9.016M
Median
Dec 2020
Revenue (Quarterly) Benchmarks
| uniQure NV | 8.485M |
| ProQR Therapeutics NV | 3.537M |
| argenx SE | 406.84M |
| Pharming Group | 81.22M |
| Pharvaris NV | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -60.15M |
| Total Expenses (Quarterly) | 56.48M |
| EPS Diluted (Quarterly) | -1.09 |
| Enterprise Value | 2.258B |
| Profit Margin (Quarterly) | -672.9% |
| Earnings Yield | -6.83% |
| Normalized Earnings Yield | -6.473 |